Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | PIONEER: avapritinib in patients with indolent systemic mastocytosis

Cem Akin • 10 Jun 2020
EHA 2020
Myeloproliferative Neoplasms Systemic Mastocytosis Avapritinib
PIONEER

Cem Akin MD, PhD, of the University of Michigan, Ann Arbor, MI, discusses the results of PIONEER (NCT03731260), a randomized, double-blind, placebo-controlled, Phase II study of avapritinib in patients with indolent systemic mastocytosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Cem Akin

ddPCR detects KIT D816V mutations with high sensitivity in systemic mastocytosis
1:43
ddPCR detects KIT D816V mutations with high sensitivity in systemic mastocytosis
Cem Akin • 11 Dec 2020
Avapritinib for indolent systemic mastocytosis in the PIONEER trial
5:14
Avapritinib for indolent systemic mastocytosis in the PIONEER trial
Cem Akin • 11 Dec 2020
Mastocytosis: impact of COVID-19 on clinical practice
1:58
Mastocytosis: impact of COVID-19 on clinical practice
Cem Akin • 10 Jun 2020

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Cem Akin • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Cem Akin • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Cem Akin • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Cem Akin • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals